Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Clinical trial NCT03829657 · TERMINATED

Trial details

NCT number: NCT03829657
Sponsor: Theravance Biopharma
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Symptomatic Neurogenic Orthostatic Hypotension MSA Parkinson's Disease (PD)Pure Autonomic Failure (PAF)

Start date: 2019-02-22
Primary completion: 2021-11-10
Enrollment: 203

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.